A Novel Psilocybin-Aspirin Conjugate: A Multifaceted Therapeutic Approach for Alzheimer's Disease and Other Neuroinflammatory/Neurological Conditions

This paper introduces a novel therapeutic conjugate that chemically links psilocin (the active form of psilocybin) and acetylsalicylic acid (aspirin). This innovative compound, with the molecular formula C21H22N2O4, is designed to capitalize on their distinct yet profoundly complementary pharmacological actions. This innova- tive compound aims to precisely target and modulate two fundamental pathological processes: neuroinflammation and neuroplasticity. While initially conceived as a groundbreaking treatment for Alzheimer’s Disease (AD), this comprehensive docu- ment articulates the compelling scientific rationale for its broad applicability across numerous high-unmet-need conditions, including Complex Regional Pain Syndrome (CRPS/RSD), Type 1 and Type 2 Diabetes, Parkinson’s Disease (PD), Multiple Sclerosis (MS), Depression and Anxiety Disorders (particularly treatment-resistant forms), Stroke Recovery, and Traumatic Brain Injury (TBI). The proposed conju- gate represents a significant advancement, offering a synergistic, multimodal ther- apeutic strategy to address complex disease mechanisms, thereby defining a novel class of pharmaceutical agents with expansive potential.